These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31684910)

  • 1. SMAD4 Y353C promotes the progression of PDAC.
    Wang Z; Li Y; Zhan S; Zhang L; Zhang S; Tang Q; Li M; Tan Z; Liu S; Xing X
    BMC Cancer; 2019 Nov; 19(1):1037. PubMed ID: 31684910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
    Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
    Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.
    Liang C; Shi S; Qin Y; Meng Q; Hua J; Hu Q; Ji S; Zhang B; Xu J; Yu XJ
    Gut; 2020 May; 69(5):888-900. PubMed ID: 31611300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
    Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
    BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.
    Singh P; Srinivasan R; Wig JD
    Pancreas; 2012 May; 41(4):541-6. PubMed ID: 22504380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis.
    Wang JD; Jin K; Chen XY; Lv JQ; Ji KW
    Oncotarget; 2017 Mar; 8(10):16704-16711. PubMed ID: 28053288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.
    Liang C; Xu J; Meng Q; Zhang B; Liu J; Hua J; Zhang Y; Shi S; Yu X
    Autophagy; 2020 Mar; 16(3):486-500. PubMed ID: 31177911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.
    Singh P; Wig JD; Srinivasan R; Radotra BD
    Indian J Cancer; 2011; 48(2):170-4. PubMed ID: 21768661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
    Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
    Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
    Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma.
    Yamazaki K; Masugi Y; Effendi K; Tsujikawa H; Hiraoka N; Kitago M; Shinoda M; Itano O; Tanabe M; Kitagawa Y; Sakamoto M
    Lab Invest; 2014 Jun; 94(6):683-91. PubMed ID: 24709776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome.
    Huang W; Navarro-Serer B; Jeong YJ; Chianchiano P; Xia L; Luchini C; Veronese N; Dowiak C; Ng T; Trujillo MA; Huang B; Pflüger MJ; Macgregor-Das AM; Lionheart G; Jones D; Fujikura K; Nguyen-Ngoc KV; Neumann NM; Groot VP; Hasanain A; van Oosten AF; Fischer SE; Gallinger S; Singhi AD; Zureikat AH; Brand RE; Gaida MM; Heinrich S; Burkhart RA; He J; Wolfgang CL; Goggins MG; Thompson ED; Roberts NJ; Ewald AJ; Wood LD
    Cancer Res; 2020 Jul; 80(13):2804-2817. PubMed ID: 32376602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma.
    Ye Y; Chen J; Zhou Y; Fu Z; Zhou Q; Wang Y; Gao W; Zheng S; Zhao X; Chen T; Chen R
    J Transl Med; 2015 Apr; 13():137. PubMed ID: 25925763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Trefoil Factor 2 From Pancreatic Duct Glands Promotes Formation of Intraductal Papillary Mucinous Neoplasms in Mice.
    Yamaguchi J; Mino-Kenudson M; Liss AS; Chowdhury S; Wang TC; Fernández-Del Castillo C; Lillemoe KD; Warshaw AL; Thayer SP
    Gastroenterology; 2016 Dec; 151(6):1232-1244.e10. PubMed ID: 27523981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma.
    Siret C; Dobric A; Martirosyan A; Terciolo C; Germain S; Bonier R; Dirami T; Dusetti N; Tomasini R; Rubis M; Garcia S; Iovanna J; Lombardo D; Rigot V; André F
    Br J Cancer; 2018 Feb; 118(4):546-557. PubMed ID: 29161242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
    Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
    Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia.
    Norris AM; Gore A; Balboni A; Young A; Longnecker DS; Korc M
    Oncogene; 2013 Aug; 32(33):3867-76. PubMed ID: 22945649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell marker nestin is critical for TGF-β1-mediated tumor progression in pancreatic cancer.
    Su HT; Weng CC; Hsiao PJ; Chen LH; Kuo TL; Chen YW; Kuo KK; Cheng KH
    Mol Cancer Res; 2013 Jul; 11(7):768-79. PubMed ID: 23552743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.